Cargando…

Combination treatment of RAD001 and BEZ235 exhibits synergistic antitumor activity via down-regulation of p-4E-BP1/Mcl-1 in small cell lung cancer

Small cell lung cancer (SCLC) is a highly malignant cancer with few targeted therapies. In the study, by mining the Cancer Cell Line Encyclopedia (CCLE) database, we found that PI3K/AKT/mTOR pathway was aberrant in 92% of SCLC cell lines. Moreover, we found that the phosphorylation level of 4E-BP1 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Bo, Wang, Huogang, Deng, Ke, Wang, Wei, Dai, Haiming, Yan Lui, Vivian Wai, Lin, Wenchu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739750/ https://www.ncbi.nlm.nih.gov/pubmed/29290965 http://dx.doi.org/10.18632/oncotarget.18984

Ejemplares similares

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo
por: Xu, Cheng-Xiong, et al.
Publicado: (2011)

The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma
por: Wang, Yao, et al.
Publicado: (2022)

Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
por: Passacantilli, Ilaria, et al.
Publicado: (2014)

Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019)

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018)

The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
por: Yu, Cheng-Chan, et al.
Publicado: (2020)

Lactobacillus rhamnosus HN001 Ameliorates BEZ235-Induced Intestinal Dysbiosis and Prolongs Cardiac Transplant Survival
por: Miao, Xiaolong, et al.
Publicado: (2022)

Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
por: Shoji, Keiko, et al.
Publicado: (2012)

Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells
por: Kim, Taewan, et al.
Publicado: (2018)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Antitumor Efficacy of Liposome-Encapsulated NVP-BEZ235 Combined with Irreversible Electroporation for Head and Neck Cancer
por: Tian, Li, et al.
Publicado: (2019)

Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015)

BEZ235: When Promising Science Meets Clinical Reality
por: Pongas, Georgios, et al.
Publicado: (2016)

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells
por: MOON, DU G., et al.
Publicado: (2014)

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016)

Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia
por: Xin, Pengliang, et al.
Publicado: (2019)

Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell
por: Zhu, Hao, et al.
Publicado: (2020)

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
por: Wang, Huanan, et al.
Publicado: (2015)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
por: Zhu, Yan, et al.
Publicado: (2015)

NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2019)

Neuroprotective effects of the anticancer drug NVP-BEZ235 (dactolisib) on amyloid-β 1–42 induced neurotoxicity and memory impairment
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2016)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis
por: Zou, Hong, et al.
Publicado: (2016)

NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
por: Li, Bihui, et al.
Publicado: (2022)

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010)

Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012)

ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration
por: Fròsina, Guido, et al.
Publicado: (2018)

NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation
por: Ruan, Banjun, et al.
Publicado: (2020)

PI3K Pathway Inhibition with NVP-BEZ235 Hinders Glycolytic Metabolism in Glioblastoma Multiforme Cells
por: Udawant, Shreya, et al.
Publicado: (2021)

PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
por: Chen, Liyan, et al.
Publicado: (2017)

Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017)

Dual PI3K/mTOR Inhibitor NVP-BEZ235 Leads to a Synergistic Enhancement of Cisplatin and Radiation in Both HPV-Negative and -Positive HNSCC Cell Lines
por: Subtil, Florentine S. B., et al.
Publicado: (2022)

NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation
por: Sun, Zhihua, et al.
Publicado: (2015)

Cell-Penetrating CaCO(3) Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma
por: Vergaro, Viviana, et al.
Publicado: (2018)

Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
por: Li, Liangqing, et al.
Publicado: (2018)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235
por: Feng, Jia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_779itj9o8bb0d7atk5sgdsavg4